Page last updated: 2024-11-05

tridecanedioic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tridecanedioic acid : An alpha,omega-dicarboxylic acid that is undecane substituted by carboxylic acid groups at positions C-1 and C-11. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10458
CHEMBL ID3187746
CHEBI ID73718
SCHEMBL ID20802
MeSH IDM0247888

Synonyms (53)

Synonym
LMFA01170014
tridecanedioic acid
505-52-2
1,11-undecanedicarboxylic acid
brassylic acid
nsc-9498
1,13-tridecanedioic acid
brassilic acid
nsc9498
1, 11-undecanedicarboxylic acid
1,11-undecanedicarboxylic acid, 94%
STK033041
T0021
tridecanedioate
A7494
NCGC00249020-01
1,11-undecanedicarboxylicacid
tox21_302982
dtxcid901683
cas-505-52-2
dtxsid9021683 ,
NCGC00256463-01
tox21_201301
NCGC00258853-01
undecane-1,11-dicarboxylic acid
CHEBI:73718 ,
AKOS005381208
nsc 9498
pl3iq40c34 ,
unii-pl3iq40c34
ec 208-011-4
einecs 208-011-4
ai3-18168
FT-0606050
brassylate
.alpha.,.omega.-tridecanedioic acid
S6063
AB01332661-02
SCHEMBL20802
CHEMBL3187746
mfcd00002740
1,13-tridecanedioate
undecane-1,11-dicarboxylate
brassilate
1,11-undecanedicarboxylate
HY-128421
Q2099072
AS-14882
CS-0099256
NCGC00249020-02
tridecanedioicacid
EN300-6476962
Z87002486
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
alpha,omega-dicarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency60.68073.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency40.20200.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency39.17530.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency39.17530.173734.304761.8120AID1346859; AID1346924
AR proteinHomo sapiens (human)Potency15.37480.000221.22318,912.5098AID1259243; AID743036
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.81770.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency67.47510.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency72.21690.003041.611522,387.1992AID1159552; AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency46.03930.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.37090.000229.305416,493.5996AID743069; AID743075; AID743079
caspase-3Homo sapiens (human)Potency33.81770.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.37620.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency111.21600.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency28.16630.037617.082361.1927AID1259364; AID1259388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's5 (55.56)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.08 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]